A systematic review of 33 studies found that people with renal cell carcinoma (RCC) show distinct microbial alterations in gut, tumor, and urinary sites compared to healthy controls, and that specific bacterial profiles correlate with better or worse responses to immunotherapy . Evidence for microbiome modulation improving outcomes remains preliminary in humans.
Researchers conducted a systematic review examining the relationship between the microbiota (microbial community composition) and renal cell carcinoma across multiple body sites. After screening over 12,000 publications, they included 33 studies that directly investigated microbiota-RCC associations. The analysis reveals a consistent pattern: RCC patients display measurable microbial dysbiosis (imbalance) at three distinct locations.
Microbial signatures in tumors and surrounding tissue. The intratumoral microbiota of kidney tumors differs substantially from adjacent healthy kidney tissue. Tumor-associated microbial communities show reduced diversity and distinct bacterial profiles compared to the microenvironment immediately surrounding the cancer. This finding is notable because it suggests the tumor itself may select for or harbor specific microbial populations that differ from healthy kidney tissue, though the review does not establish whether this represents a cause or consequence of malignant transformation.
Gut dysbiosis in RCC patients. The systemic analysis identified consistent dysbiotic patterns in stool samples from RCC patients relative to healthy controls. RCC-associated dysbiosis is characterized by enrichment of potentially pro-carcinogenic bacterial taxa and depletion of protective bacteria. The review identifies specific metabolic byproducts as potential mechanistic links: bacterial-derived metabolites including tryptophan-kynurenine pathway intermediates, short-chain fatty acids, and trimethylamine N-oxide (TMAO) may influence the tumor microenvironment, systemic immune response, and metastatic potential. However, the review notes that most evidence for these mechanistic pathways remains derived from animal models or in vitro studies rather than human trials.
Microbiota composition predicts immunotherapy response. A key finding with potential clinical relevance concerns gut microbiota and checkpoint inhibitor efficacy. Studies identified in the review demonstrate that higher microbial diversity correlates with improved response to immune checkpoint inhibitors in RCC patients. Specific bacterial taxa, particularly Akkermansia muciniphila, were associated with better treatment outcomes. Conversely, dysbiosis and antibiotic exposure were linked to diminished immunotherapy efficacy. This association suggests the microbiota may play a functional role in generating or maintaining anti-tumor immunity. The review also notes that urinary microbiome changes occur in RCC, though data remain limited compared to gut and tumor-site findings.
Microbiome modulation and treatment outcomes. Several included studies examined whether deliberately modifying the microbiota through probiotics, prebiotics, or fecal microbiota transplantation (FMT) could enhance antitumor immunity and improve treatment responses. The review reports that such interventions showed promise in enhancing antitumor immunity in experimental settings, but crucially notes that clinical data specifically addressing RCC onset, progression, or therapeutic outcomes remain limited in humans. This distinction is important: most evidence for microbiome-directed interventions comes from animal studies or preliminary human data rather than large randomized controlled trials.
The microbiota-cancer relationship is an active research frontier, but several limitations apply to practical interpretation:
On prevention. Current evidence does not support recommending specific microbiome interventions to prevent kidney cancer in healthy people. The review identifies associations between dysbiosis and RCC but does not establish causation. General practices that support healthy microbiota composition, such as consuming high-fiber diet foods and fermented foods, remain reasonable based on broader microbiota research, but these have not been validated specifically for RCC prevention.
On treatment. If you have RCC and are considering or undergoing immunotherapy, microbiota composition appears relevant to treatment response. Antibiotic exposure (particularly broad-spectrum antibiotics) may warrant discussion with your oncology team if alternatives exist, given the observed association between antibiotic use and reduced immunotherapy efficacy. Whether targeted probiotic supplementation, prebiotic intake, or other microbiota-modulating interventions improve outcomes in RCC patients specifically remains unknown. Any such strategy should be discussed with your oncologist, as the clinical evidence does not yet support standalone microbiome-targeted approaches for RCC management.
On research trajectory. The field is moving toward mechanistic understanding of how microbiota influence cancer immunity. Akkermansia muciniphila and other identified taxa may eventually become clinically relevant biomarkers or intervention targets, but this requires validation in larger human trials. Clinical translation typically takes years beyond initial associations.
| Aspect | Details |
|---|---|
| Study type | Systematic review and meta-analysis |
| Studies included | 33 directly examining microbiota-RCC relationships (from 12,547 screened publications) |
| Guideline adherence | PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) |
| Primary databases searched | PubMed, Scopus |
| Sample size | Not reported (aggregate across 33 included studies) |
| Journal | Urologiia (Moscow, Russia: 1999) |
| PubMed ID | 42687557 |
| Key finding | Gut dysbiosis correlates with RCC; microbiota composition influences immunotherapy response |
| Evidence tier | A tier for associations; B-C tier for mechanistic claims; D tier for clinical microbiome interventions in RCC |
PubMed: https://pubmed.ncbi.nlm.nih.gov/42687557/
Disclaimer: This summary describes research findings, not clinical recommendations. Kidney cancer is a serious malignancy requiring professional medical management. Discuss any changes to treatment strategy or supplementation with your oncology team.
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.